Cargando…
Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
The targeting of activated epidermal growth factor receptor (EGFR) with therapeutic anti-EGFR monoclonal antibodies (mAbs) such as cetuximab and panitumumab has been used as an effective strategy in the treatment of colorectal cancer (CRC). However, its clinical efficacy occurs only in a limited num...
Autores principales: | Kim, Sujin, Kim, Nayoung, Kang, Keunsoo, Kim, Wonkyung, Won, Jonghwa, Cho, Jeonghee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721647/ https://www.ncbi.nlm.nih.gov/pubmed/31409052 http://dx.doi.org/10.3390/cells8080878 |
Ejemplares similares
-
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
por: Cho, Jeonghee, et al.
Publicado: (2014) -
Autophosphorylation of the carboxyl‐terminal domain is not required for oncogenic transformation by lung‐cancer derived EGFR mutants
por: Cho, Jeonghee, et al.
Publicado: (2018) -
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010) -
Immunohistochemical Analysis of the Expression of Adhesion Proteins: TNS1, TNS2 and TNS3 in Correlation with Clinicopathological Parameters in Gastric Cancer
por: Nizioł, Marcin, et al.
Publicado: (2021) -
Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)